Lv5
1170 积分 2025-04-11 加入
Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of N-Acetylgalactosamine–Conjugated Small Interfering RNA Disposition and Gene Silencing in Preclinical Species and Humans
1天前
求助中
Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of N-Acetylgalactosamine–Conjugated Small Interfering RNA Disposition and Gene Silencing in Preclinical Species and Humans
1天前
已完结
Nonclinical Pharmacokinetics and Absorption, Distribution, Metabolism, and Excretion of Givosiran, the First Approved N-Acetylgalactosamine–Conjugated RNA Interference Therapeutic
4天前
已完结
Mechanistic Pharmacokinetics and Pharmacodynamics of GalNAc-siRNA: Translational Model Involving Competitive Receptor-Mediated Disposition and RISC-Dependent Gene Silencing Applied to Givosiran
4天前
已完结
Mechanistic Pharmacokinetics and Pharmacodynamics of GalNAc-siRNA: Translational Model Involving Competitive Receptor-Mediated Disposition and RISC-Dependent Gene Silencing Applied to Givosiran
5天前
已完结
Pharmacokinetic and Pharmacodynamic Modeling of siRNA Therapeutics – a Minireview
15天前
已完结
In Vitro - in Vivo Extrapolation of Hepatic Clearance in Preclinical Specie
2个月前
已完结
Absorption, Distribution, Metabolism, and Excretion of US Food and Drug Administration–Approved Antisense Oligonucleotide Drugs
3个月前
已完结
A Review on Commercial Oligonucleotide Drug Products
3个月前
已完结
First-In-Human, Single Ascending Dose and Food-Effect Study in Healthy Volunteers of SUL-238, a Novel Orally Administered Mitochondria-Directed Drug Candidate
4个月前
已关闭
皖公网安备34019202002308
